Xenikos Overview

  • Founded

  • 2009

Founded
  • Status

  • Private

  • Employees

  • 17

Employees
  • Latest Deal Type

  • Later Stage VC

  • Latest Deal Amount

  • $47.1M

  • Investors

  • 8

Xenikos General Information

Description

Developer of anti-T-cell antibodies designed to provide immunotherapy medicines to help restore patients' health. The company uses a therapeutic tool for resetting the body's immune system which once injected into the body, specifically identifies and eliminates adult T cells, with a strong preference for the activated ones, enabling the medical community to optimize treatment outcomes associated with serious immune diseases.

Contact Information

Website
www.xenikos.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Drug Delivery
Biotechnology
Primary Office
  • Wilhelminasingel 14
  • 6524 AL Nijmegen
  • Netherlands
+31 024 000 0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Xenikos Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Later Stage VC 02-Sep-2021 $47.1M 000.00 Completed Clinical Trials - Phase 3
4. Later Stage VC (Series B) 15-May-2018 0000 000.00 Completed Pre-Clinical Trials
3. Grant 03-Jan-2017 00.000 00.00 Completed Pre-Clinical Trials
2. Later Stage VC 14-Oct-2016 $2.24M $9.1M Completed Pre-Clinical Trials
1. Early Stage VC (Series A) 19-Jun-2012 $6.9M $6.9M Completed Pre-Clinical Trials
To view Xenikos’s complete valuation and funding history, request access »

Xenikos Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of anti-T-cell antibodies designed to provide immunotherapy medicines to help restore patients' health. The co
Drug Discovery
Nijmegen, Netherlands
17 As of 2022
000.00
0000000000 0 000.00

000-00

t dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamc
0000 000000000
Evry Cedex, France
00 As of 0000
000.00
00000000000 000.00

000000

sum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididun
0000 000000000
Cambridge, MA
000
00.00 0000-00-00
00000000000 000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Xenikos Competitors (29)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
PEP-Therapy Venture Capital-Backed Evry Cedex, France 00 000.00 00000000000 000.00
0000000 Venture Capital-Backed Cambridge, MA 000 00000000000 000
0000000 0000000000 Venture Capital-Backed Cambridge, MA 000 00000 00000000000 00000
0000000 0000000000 Venture Capital-Backed South San Francisco, CA 00 00000 00000000000 00000
0000000 000000 Formerly VC-backed Lyon, France 000 00000 00000000 00000
You’re viewing 5 of 29 competitors. Get the full list »

Xenikos Patents

  • 9

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 1

    Granted

  • 000

    Pending

  • 000

    Expiring in next 12 mo

Xenikos Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2018357984-A2 Immunotoxins, formulations thereof and their use in medicine Pending 31-Oct-2017 00000000000
CA-3080873-A1 Immunotoxins, formulations thereof and their use in medicine Pending 31-Oct-2017 00000000000
EP-3703748-A1 Immunotoxins, formulations thereof and their use in medicine Pending 31-Oct-2017 00000000000
GB-201717966-D0 Immunotoxins, formulations thereof and their use in medicine Inactive 31-Oct-2017 00000000000
AU-2018357984-A1 Immunotoxins, formulations thereof and their use in medicine Pending 31-Oct-2017 C07K16/2809
To view Xenikos’s complete patent history, request access »

Xenikos Executive Team (8)

Name Title Board Seat Contact Info
Ypke van Oosterhout Ph.D Founder, Chief Executive Officer & Board Member
André De Lege Chief Financial Officer & Accountant, Controller
Maarten Frijlink Chief Operating Officer
Eric van Hooren Chief Development Officer
Hassan Aly MD Chief Medical Officer
You’re viewing 5 of 8 executive team members. Get the full list »

Xenikos Board Members (16)

Name Representing Role Since
Derek DiRocco Ph.D RA Capital Management Board Observer 000 0000
Douglas Williams Ph.D Self Chairman 000 0000
Francesco De Rubertis Ph.D Medicxi Board Member 000 0000
Jake Simson Ph.D RA Capital Management Board Member 000 0000
Jon Edwards Ph.D Medicxi Board Member 000 0000
You’re viewing 5 of 16 board members. Get the full list »

Xenikos Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Xenikos Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Veloxis Pharmaceuticals Corporation 000 0000 000000 0
Medicxi Venture Capital Minority 000 0000 000000 0
Meneldor Venture Capital Minority 000 0000 000000 0
RA Capital Management Hedge Fund Minority 000 0000 000000 0
Stitching Participatie Xenikos Corporation Minority 000 0000 000000 0
You’re viewing 5 of 8 investors. Get the full list »

Ready to get started?

Request a free trial